TipRanks
Advertisement
Advertisement
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
PremiumThe FlyVanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
1M ago
VNDA Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
VNDA Upcoming Earnings Report: What to Expect?
2M ago
Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab
Premium
The Fly
Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab
2M ago
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
PremiumThe FlyVanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
4M ago
Vanda Pharmaceuticals Bets Big on Growth Pipeline
Premium
Company Announcements
Vanda Pharmaceuticals Bets Big on Growth Pipeline
4M ago
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
Premium
The Fly
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
5M ago
Vanda Pharmaceuticals announces commercial availability for Nereus
PremiumThe FlyVanda Pharmaceuticals announces commercial availability for Nereus
5M ago
Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
Premium
Company Announcements
Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
5M ago
AnaptysBio price target lowered to $60 from $90 at UBS
Premium
The Fly
AnaptysBio price target lowered to $60 from $90 at UBS
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100